Novel Penetrating Peptides Deliver PROTAC Cancer Drugs Into Leukemia and Lymphoma Cells
Researchers developed 26 novel cell-penetrating peptides for blood cancers, with two top candidates significantly enhancing PROTAC delivery into leukemia cells and improving Bcr-Abl protein degradation.
Quick Facts
What This Study Found
Two novel penetrating peptides (C9C-f(3Bta) and Cyclo-C9C-R) significantly enhanced intracellular PROTAC content in K562 leukemia cells, facilitated Bcr-Abl protein degradation, reduced STAT5 phosphorylation, and promoted apoptosis.
Key Numbers
Novel penetrating peptides demonstrated enhanced PROTAC delivery specifically into leukemia and lymphoma cells.
How They Did This
Designed and screened 26 novel targeted penetrating peptides for leukemia/lymphoma cells. Assessed membrane permeability, cancer targeting, and stability. Combined top candidates with IMA-PROTAC and evaluated anti-proliferative activity, Bcr-Abl degradation, STAT5 signaling, apoptosis, and cell cycle effects. Quantified intracellular PROTAC by HPLC-MRM-MS.
Why This Research Matters
PROTACs represent the next frontier of cancer therapy, but their poor cell entry is a major limitation. Cancer-targeting peptides that solve this delivery problem could unlock PROTAC therapy for blood cancers and potentially many other cancer types.
The Bigger Picture
PROTACs are widely considered the next generation of targeted cancer therapy, but delivery remains their Achilles heel. This study demonstrates that cancer-specific cell-penetrating peptides can bridge the gap, turning PROTACs from laboratory tools into potentially viable cancer drugs. The approach could be generalizable to PROTAC delivery across many cancer types.
What This Study Doesn't Tell Us
In vitro cell culture study using cancer cell lines. In vivo efficacy, pharmacokinetics, and selectivity need demonstration. Peptide stability in blood and tissue penetration in living systems are unknown. The peptide-PROTAC combination approach adds manufacturing complexity.
Questions This Raises
- ?Do these penetrating peptides maintain selectivity for cancer cells over normal cells in vivo?
- ?Can this approach be applied to PROTACs targeting other cancer-driving proteins beyond Bcr-Abl?
- ?What are the pharmacokinetic properties and in vivo stability of these peptide-PROTAC combinations?
Trust & Context
- Key Stat:
- 26 peptides designed with two top candidates significantly boosting PROTAC delivery into leukemia cells and enhancing cancer protein destruction
- Evidence Grade:
- Preliminary evidence: proof-of-concept in vitro study published in the European Journal of Medicinal Chemistry. Promising but requires in vivo validation.
- Study Age:
- Published in 2024. Addresses a critical limitation of PROTAC cancer drugs.
- Original Title:
- Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery.
- Published In:
- European journal of medicinal chemistry, 277, 116734 (2024)
- Authors:
- Zhang, Qingqing(2), Liu, Yuying, Zhang, Jie(7), Li, Yanchen, Wang, Jin, Liu, Nanxin, Zhang, Jie(7), Pan, Xiaoyan
- Database ID:
- RPEP-09651
Evidence Hierarchy
Frequently Asked Questions
What are PROTACs and why do they need peptide help?
PROTACs are drugs that tag cancer proteins for destruction by the cell's own recycling system. They can target proteins that traditional drugs cannot. However, PROTACs are large molecules that struggle to enter cells — cell-penetrating peptides act as delivery vehicles to solve this problem.
Could this help treat leukemia?
These peptides specifically enhanced delivery of a PROTAC targeting Bcr-Abl, the protein driving chronic myeloid leukemia. If this works in animal models and clinical trials, it could provide a new treatment approach for leukemia patients, especially those resistant to current drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09651APA
Zhang, Qingqing; Liu, Yuying; Zhang, Jie; Li, Yanchen; Wang, Jin; Liu, Nanxin; Zhang, Jie; Pan, Xiaoyan. (2024). Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery.. European journal of medicinal chemistry, 277, 116734. https://doi.org/10.1016/j.ejmech.2024.116734
MLA
Zhang, Qingqing, et al. "Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery.." European journal of medicinal chemistry, 2024. https://doi.org/10.1016/j.ejmech.2024.116734
RethinkPeptides
RethinkPeptides Research Database. "Discovery of novel penetrating peptides able to target human..." RPEP-09651. Retrieved from https://rethinkpeptides.com/research/zhang-2024-discovery-of-novel-penetrating
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.